Tirzepatide
Batch #010012 · Research use only.
Supreme Peptides Research Grade
Tirzepatide is a novel dual-agonist peptide studied for its ability to activate both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. In research settings, it has gained significant attention for its integrative role in regulating appetite, insulin signaling, and energy balance.
Product overview
Tirzepatide is a research-grade synthetic peptide engineered to simultaneously target incretin pathways involved in metabolic control. Preclinical and clinical research associate Tirzepatide with improved glucose utilization, appetite modulation, and enhanced metabolic efficiency. Its dual-receptor mechanism makes it a valuable tool for studying complex metabolic conditions and adaptive weight-management processes.
Key research features
Dual incretin receptor activation:
Tirzepatide is widely studied for its ability to activate both GLP-1 and GIP receptors, supporting research into synergistic effects on insulin signaling and metabolic regulation.
Appetite and weight-regulation research:
Studies suggest Tirzepatide may influence satiety signaling and caloric intake through central and peripheral pathways, making it relevant for experimental models focused on obesity and weight management.
Glucose metabolism and insulin sensitivity:
Research indicates Tirzepatide may improve glucose homeostasis and insulin response, supporting its use in studies examining metabolic health and energy balance.
Tirzepatide Suggested Use:
Typical Dose: 2.5–15 mg per week
Route: Subcutaneous injection
Frequency: Once weekly
Duration: As recommended by a healthcare professional